论文部分内容阅读
AIM:Portopulmonary hypertension is a serious complicationof chronic liver disease.Our aim was to search into theeffect of terlipressin on systolic pulmonary artery pressureamong cirrhotic patients.METHODS:Twelve patients(6 males and 6 females)withliver cirrhosis were recruited in the study.Arterial bloodgas samples were obtained in sitting position at rest.Contrastenhanced echocardiography and measurements of systolicpulmonary artery pressure were performed before and afterthe intravenous injection of 2 mg terlipressin.RESULTS:Of 12 patients studied,the contrast enhancedechocardiography was positive in 5,and the positivefindings in contrast enhanced echocardiography werereversed to normal in two after terlipressin injection.Themean systolic pulmonary artery pressure was 25.5±3.6 mmHgbefore terlipressin injection,and was 22.5+2.5 mmHg afterterlipressin(P=0.003).The systolic pulmonary arterypressure was above 25 mmHg in seven of these 12 patients.After the terlipressin injection,systolic pulmonary arterypressure was<25 mmHg in four of these cases(58.3% vs25%,P=0.04).CONCLUSION:Terlipressin can decrease the systolicpulmonary artery pressure in patients with liver cirrhosis.
AIM: Portopulmonary hypertension is a serious complication of chronic liver disease. Our aim was to search into the effect of terlipressin on systolic pulmonary artery pressure among cirrhotic patients. METHODS: Twelve patients (6 males and 6 females) withliver cirrhosis were recruited in the study. Arterial bloodgas samples were obtained in sitting position at rest. Contrasttenhanced echocardiography and measurements of systolic pulmonary artery pressure were performed before and afterthe intravenous injection of 2 mg terlipressin .RESULTS: Of 12 patients studied, the contrast enhancechocardiography was positive in 5, and the positive bindings in contrast enhanced echocardiography werereversed to normal in two after terlipressin injection.Themean systolic pulmonary artery pressure was 25.5 ± 3.6 mmHgbefore terlipressin injection, and was 22.5 + 2.5 mmHg afterterlipressin (P = 0.003). The systolic pulmonary arterypressure was above 25 mmHg in seven of these 12 patients .After the terlipressin injection, systoli cCLP was <25 mmHg in four of these cases (58.3% vs 25%, P = 0.04) .CONCLUSION: Terlipressin can decrease the systolic pulmonary artery pressure in patients with liver cirrhosis.